Transgene

Transgene CapEx/D&A

The CapEx to Depreciation Ratio of Transgene (TNG.PA) as of Nov 18, 2026 is 2.27. In the previous year, CapEx to Depreciation Ratio was 1.68 — a change of 34.76% (higher).

CapEx/D&A

2.27

YoY

34.76%

Last updated:

CapEx to Depreciation Ratio of Transgene is 2024 2.27 . CapEx to Depreciation Ratio of Transgene was 2023 1.68 . It decreases by 34.76% higher compared to the previous year.

The Transgene CapEx/D&A history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/D&A
Date
CapEx/D&A
Jan 1, 2017
0.23 EUR
Jan 1, 2018
0.72 EUR
Jan 1, 2019
0.92 EUR
Jan 1, 2020
0.46 EUR
Jan 1, 2021
0.37 EUR
Jan 1, 2022
0.89 EUR
Jan 1, 2023
1.68 EUR
Jan 1, 2024
2.27 EUR
The Transgene CapEx/D&A history
YEARCapEx/D&AYoY
2.27+34.76%
1.68+87.93%
0.89+143.64%
0.37-20.03%
0.46-50.32%
0.92+29.04%
0.72+216.57%
0.23+1,607.28%
0.01-97.71%
0.58-28.22%
0.81—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

CapEx to Depreciation Ratio of Transgene is 2.27 in 2024.

CapEx to Depreciation Ratio of Transgene changed from 1.68 to 2.27, representing a 34.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Depreciation Ratio Transgene since 2006 – with annual values, charts, and detailed analysis.

The CapEx/D&A ratio compares investment spending to asset depreciation. Ratios above 1.0x indicate the company is growing its asset base, below 1.0x suggests underinvestment.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Depreciation Ratio's Transgene with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Depreciation Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Depreciation Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Transgene

All Key Metrics — Transgene